[1] Pal P,Singh B,Kane S,et al.Bone metastases in follicular carcinoma of thyroid［J］.Indian J Otolaryngol Head Neck Surg,2018,70(1):10-14.
[2] Sun KX,Zheng RS,Zeng HM,et al.The incidence and mortality of lung cancer in China,2014［J］.Chinese Journal of Oncology,2018,40(11):805-811.
[3] Somma J,Schlecht NF,Fink D,et al.Thyroid fine needle aspiration cytology:Follicular lesions and the gray zone［J］.Acta Cytol,2010,54(2):123-131.
[4] Gupta P,Bardia A,Rajwanshi A,et al.Cytodiagnosis of distant metastases from follicular thyroid carcinoma［J］.Diagn Cytopathol,2016,44(2):108-112.
[5] Bae JS,Kim Y,Jeon S,et al.Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation［J］.Diagn Pathol,2016(11):21.
[6] Macerola E,Torregrossa L,Ugolini C,et al.BRAF(K601E) mutation in a follicular thyroid adenoma:A case report［J］.Int J Surg Pathol,2017,25(4):348-351.
[7] Pstrag N,Ziemnicka K,Bluyssen H,et al.Thyroid cancers of follicular origin in a genomic light:In-depth overview of common and unique molecular marker candidates［J］.Mol Cancer,2018,17(1):116.
[8] Baloch ZW,Livolsi VA.Fine-needle aspiration of thyroid nodules:Past,present,and future［J］.Endocr Pract,2004,10(3):234-241.
[9] Nikiforova MN,Lynch RA,Biddinger PW,et al.RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors:Evidence for distinct molecular pathways in thyroid follicular carcinoma［J］.J Clin Endocrinol Metab,2003,88(5):2318-2326.
[10] Swierniak M,Pfeifer A,Stokowy T,et al.Somatic mutation profiling of follicular thyroid cancer by next generation sequencing［J］.Mol Cell Endocrinol,2016(433):130-137.
[11] Jung CK,Kim Y,Jeon S,et al.Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors［J］.Hum Pathol,2018(81):9-17.
[12] Lamartina L,Grani G,Durante C,et al.Recent advances in managing differentiated thyroid cancer［J］.F1000 Res,2018(7):86.
[13] WANG Jinghai，CHEN Liang，ZHAO Zijun.Analysis on imaging features of bone metastases from thyroid carcinoma［J］.Health Medicine Research and Practic,2013,10(03):54-55.［王静海,陈亮,赵梓君.甲状腺癌骨转移影像学特点分析［J］.保健医学研究与实践,2013,10(03):54-55.］
[14] ZHANG Shulong,ZHAN Lei.Clinical significance of SPECT/CT 99TcmO4- imaging in differentiated thyroid carcinoma before 131I treatment［J］.China Modern Medicine,2017,24(1):122-124,131.［张树龙,战雷.分化型甲状腺癌131I治疗前99TcmO4- SPECT/CT显像的临床意义［J］.中国当代医药,2017,24(1):122-124,131.］
[15] YU Yongli,LUO Quanyong,CHEN Libo,et al.Survival of patients with differentiated thyroid carcinoma after thyroidectomy and 131I therapy［J］.Chinese Journal of Nuclear Medicine,2006,26(5):261-263.［余永利,罗全勇,陈立波,等.分化型甲状腺癌术后131I治疗生存率分析［J］.中华核医学杂志,2006,26(5):261-263.］
[16] Chinese Society of Nuclear Medicine.2014 131I guidelines for the treatment of differentiated thyroid cancer［J］.Chinese Journal of Nuclear Medicine and Molecular Imaging,2014,34(4):264-278.［中华医学会核医学分会.131I治疗分化型甲状腺癌指南(2014版)［J］.中华核医学与分子影像杂志,2014,34(4):264-278.］